BUZZ-LAVA Therapeutics jumps on merger or sale talks, cuts 30% of jobs

Reuters

Feb 25, 2025

BUZZ-LAVA <a href="https://laohu8.com/S/LENZ">Therapeutics</a> jumps on merger or sale talks, cuts 30% of jobs

** Shares of LAVA Therapeutics LVTX.O rise 27.4% to $1.20 premarket, after drug developer says it is evaluating strategic options, including a potential sale or merger

** Co says it will continue to enroll patients in the early-stage clinical study of LAVA-1266 for treating hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome

** Co also has implemented a restructuring plan, which includes a workforce reduction of about 30% to reduce costs and conserve cash

** As of Dec 31, 2023, co had 35 full-time employees - SEC filing

** Co estimates it will incur $500,000 in one-time costs related to the workforce reduction in Q1 2025

** LVTX had $76.6 mln in cash as of Dec 31, 2024

** LVTX fell 45.7% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514092754"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514092754\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514092754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514092754","market":"us","top_or_hot":-1,"title":"BUZZ-LAVA Therapeutics jumps on merger or sale talks, cuts 30% of jobs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-LAVA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumps on merger or sale talks, cuts 30% of jobs</title></head><body><p>** Shares of LAVA Therapeutics <span>LVTX.O</span> rise 27.4% to $1.20 premarket, after drug developer says it is evaluating <span>strategic options</span>, including a potential sale or merger</p><p>** Co says it will continue to enroll patients in the early-stage clinical study of LAVA-1266 for treating hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome </p><p>** Co also has implemented a restructuring plan, which includes a workforce reduction of about 30% to reduce costs and conserve cash</p><p>** As of Dec 31, 2023, co had 35 full-time employees - SEC filing</p><p>** Co estimates it will incur $500,000 in one-time costs related to the workforce reduction in Q1 2025</p><p>** LVTX had $76.6 mln in cash as of Dec 31, 2024</p><p>** LVTX fell 45.7% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-LAVA Therapeutics jumps on merger or sale talks, cuts 30% of jobs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-LAVA Therapeutics jumps on merger or sale talks, cuts 30% of jobs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-25 22:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-LAVA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumps on merger or sale talks, cuts 30% of jobs</title></head><body><p>** Shares of LAVA Therapeutics <span>LVTX.O</span> rise 27.4% to $1.20 premarket, after drug developer says it is evaluating <span>strategic options</span>, including a potential sale or merger</p><p>** Co says it will continue to enroll patients in the early-stage clinical study of LAVA-1266 for treating hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome </p><p>** Co also has implemented a restructuring plan, which includes a workforce reduction of about 30% to reduce costs and conserve cash</p><p>** As of Dec 31, 2023, co had 35 full-time employees - SEC filing</p><p>** Co estimates it will incur $500,000 in one-time costs related to the workforce reduction in Q1 2025</p><p>** LVTX had $76.6 mln in cash as of Dec 31, 2024</p><p>** LVTX fell 45.7% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3N3PG1BC:1","article_id":"2514092754","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514092754","pubTimestamp":1740492978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-LAVA Therapeutics jumps on merger or sale talks, cuts 30% of jobs** Shares of LAVA Therapeutics LVTX.O rise 27.4% to $1.20 premarket, after drug developer says it is evaluating strategic options, including a potential sale or merger** Co says it will continue to enroll patients in the early-stage clinical study of LAVA-1266 for treating hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome ** Co also has implemented a restructuring plan, which includes a workforce reduction of about 30% to reduce costs and conserve cash** As of Dec 31, 2023, co had 35 full-time employees - SEC filing** Co estimates it will incur $500,000 in one-time costs related to the workforce reduction in Q1 2025** LVTX had $76.6 mln in cash as of Dec 31, 2024** LVTX fell 45.7% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LVTX":"LAVA Therapeutics N.V.","BK4539":"次新股"},"translate_title":"BUZZ-LAVA Therapeutics因合并或出售谈判而大幅裁员30%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LVTX":0.9},"content_text":"BUZZ-LAVA Therapeutics jumps on merger or sale talks, cuts 30% of jobs** Shares of LAVA Therapeutics LVTX.O rise 27.4% to $1.20 premarket, after drug developer says it is evaluating strategic options, including a potential sale or merger** Co says it will continue to enroll patients in the early-stage clinical study of LAVA-1266 for treating hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome ** Co also has implemented a restructuring plan, which includes a workforce reduction of about 30% to reduce costs and conserve cash** As of Dec 31, 2023, co had 35 full-time employees - SEC filing** Co estimates it will incur $500,000 in one-time costs related to the workforce reduction in Q1 2025** LVTX had $76.6 mln in cash as of Dec 31, 2024** LVTX fell 45.7% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}